Background: Lopinavir is a potent protease inhibitor (PI) used for the treatment of HIV infection. Different lopinavir target trough concentrations (C troughs ) were previously determined according to patient treatment histories: 1 mg/l for PI-naive patients, and 4 and 5.7 mg/l for PI-experienced patients. However, the probability to achieve these target C troughs with the current 400 mg twice-daily or 800 mg once-daily doses of the new tablet form, and the influence of body weight on this probability are unknown. Methods: A population pharmacokinetic model for lopinavir was developed using data from 424 HIV type-1-infected patients, and the final model was used to estimate the probability to achieve target C troughs via Monte Carlo simulations.
, Jean-Pierre Morini 2, 7 , Stéphanie Chhun 1, 2, 3 , Anne Krivine 2, 8 , Dominique Salmon 1, 2, 9 , Nicolas Dupin 1, 2, 7 , Laurence Weiss 1, 2, 5 , Olivier Lortholary 1, 2, 6 , Gérard Pons 1, 2, 3 , Odile Launay 1, 2, 4, 9 and Jean-Marc Treluyer Introduction concentration observed just before a new intake, and its antiviral efficacy has been suggested. To date, three different target C troughs have been established: 1, 4 and 5.7 mg/l. The 1 mg/l cutoff value for PI-naive patients was suggested for both children [3] and adults [4] . For PI-pretreated patients, described target C troughs range between 4 and 5.7 mg/l. The 4 mg/l cutoff value was found to be the concentration above which the probability for PI-pretreated patients to reach an undetectable viral load was significantly increased [5] . In salvage therapy for heavily pretreated patients, Boffito et al. [6] determined an efficacy threshold of 5.7 mg/l to achieve and maintain an undetectable viral load. The existence of target concentrations strongly suggests the need for individualizing LPV dose using therapeutic drug monitoring. However, the relevance of therapeutic drug monitoring depends on the ability of the recommended dosage regimen to achieve the efficacy threshold. A previous study, which included patients receiving the previous capsule formulation of LPV, has shown that an important risk of underexposure occurred with the recommended 400/100 mg of LPV/RTV for PI-experienced patients, and that this risk further increased for a body weight >70 kg [7] . However, these results should be reassessed, as a new tablet formulation of LPV/RTV, which is characterized by some modifications in the pharmacokinetics of LPV compared with the capsule form, became available 2 years ago. Indeed, the new form provides a moderate increase in LPV exposure associated with a decrease in its intraindividual variability and in the sensitivity of LPV bioavailability to food effect [8] .
Because of these differences, a population pharmacokinetic study performed on the new tablet form is warranted in order to update the probabilities to achieve the target concentrations at the recommended 400/100 mg twice daily or 800/200 mg once daily doses of LPV/RTV, and to confirm the possible influence of body weight on these probabilities. Such a model could also contribute to investigating the usefulness of a dose adjustment in the case of underexposure. Thus, we decided to evaluate the influence of body weight on the pharmacokinetics of LPV, under its new tablet form, and on the probability to achieve target C troughs via a population approach.
Methods

Patients and treatment
The population comprised adult patients receiving LPV for the treatment of HIV infection. All patients were monitored using the plasma concentrations of antiretroviral drugs on a routine basis. Samples were drawn after at least 2 weeks of treatment in order to be at steady state. For each patient, the time that elapsed between administration and sampling, gender, body weight, ethnicity (Caucasian, Black, that is from French West Indies or sub-Saharian Africa, and Asian) and age were carefully recorded, as were associated treatments, particularly antiretroviral drugs. Viral loads were also obtained if they were determined concomitantly to LPV assay (that is, ±15 days). Patients with liver cirrhosis or with biological signs of hepatic injury (liver enzymes >145 U/l) were not considered for the study.
Because of the current knowledge in LPV pharmacokinetics, the samples corresponding to concentrations <0.1 mg/l were assumed to reflect a lack of compliance and excluded. Furthermore, samples coming from pregnant women were not analysed, as well as samples coming from patients supplemented with RTV (given by Norvir ® ) or cotreated with drugs known as CYP3A4 inductors or inhibitors others than antiretroviral (for example, antituberculosis and antifungals). These data were excluded in order to avoid a possible bias in the mean population parameter estimates.
Analytical methods
The assay for LPV was performed by using high pressure liquid chromatography with UV detection. Briefly, 500 µl of sodium carbonate (0. , and 100 µl of this mixture was injected into the chromatographic system. The separation was performed on a Nucleosil C8 column (125×4.6 mm, 3 µm) at a flow rate of 1 ml/min. Detection was performed at 205 nm. The quantification limit of the method was 0.10 mg/l, with the interassay precision and bias being <7% in the calibration range of 0.1-20 mg/l.
Population pharmacokinetic modelling
Concentration-time data were analysed by the use of the first-order conditional estimation with interaction method of the non-linear mixed-effects modelling programme NONMEM ® (version VI 2.0) [9] . Several structural pharmacokinetic models were investigated. Classical one-and two-compartment models with first-and zero-order absorption were also evaluated. Several error models (that is, proportional, exponential, and additive random effects models) were also investigated as means of describing interpatient and residual variabilities. Systematic testing for the influence of continuous covariates on the pharmacokinetic parameters was done using the following equation for CL/F and body weight: CL/F= typical value of CL/F×(body weight/median body weight) θ , where the typical value of the CL/F was for a patient with the median covariate value, and θ was the influential factor for body weight.
Binary covariates (gender and combined treatment) were investigated as follows: CL/F =typical value of CL/ F× sex, where sex was equal to 1 for male and to the influential factor for female. Ethnicity was investigated as categorical covariate as follows: CL/F =typical value of CL/F×FLAG1×FLAG2×FLAG3, where FLAG1 was equal to θ 1 for Caucasians and to 1 otherwise, FLAG2 was equal to θ 2 for Blacks and to 1 otherwise and FLAG3 was equal to θ 3 for Asians or to 1 otherwise.
To investigate circadian variation, the value of the influential factor was fixed to 1 when the concentration corresponded to a morning intake and was estimated by NONMEM when LPV concentration corresponded to an evening intake. Combined drugs were first integrated separately in the model and then cotreatments found to induce LPV clearance were included concomitantly. The combination responsible for the greater objective function decrease was kept. The possible effect of a covariate on LPV bioavailability was investigated as described above by estimation of the same influential factor on both CL/F and apparent distribution volume (V/F). The significance of a relationship between a pharmacokinetic parameter and a covariate was assessed by use of the χ 2 test of the difference between the objective functions of the basic model (without the covariate) and the model with the covariate. A covariate was retained in the model if it produced a minimum decrease in the objective function of 4 units (1 degree of freedom; P=0.05) and if its effect was biologically plausible. An intermediate multivariate model that included all selected covariates was then obtained. A covariate was retained in the final multivariate model if its deletion from the intermediate model led to a 7-point increase in the objective function (1 degree of freedom; P=0.01). At each step, the goodness of fit was evaluated by use of the graphs representing the normalized prediction errors versus time after administration of the dose and predicted concentrations.
Model validation
The accuracy and robustness of the final population model were assessed by a visual predictive check. The final population model parameters were used to perform 500 simulations of the database. The 2.5th and the 97.5th percentiles as well as the 50th (median) percentile of simulated concentrations were plotted against observed concentrations.
A lack of bias was also requested for the graphs representing the normalized prediction errors versus predicted concentrations and time after dose.
Evaluation of lopinavir dosing regimens
The possible influence of body weight on the probability to achieve the target C troughs was investigated by the use of Monte Carlo simulations. These simulations (10,000 simulated patients per body weight) were performed for five different body weights (50, 60, 70, 80 and 90 kg) and for three different dosing regimens (400/100 mg and 600/150 mg twice daily, and 800/200 mg once daily). Simulated C troughs were obtained and the probability to achieve the chosen target C trough was calculated by dividing the number of simulated C troughs greater than or equal to the target value by the total number of simulated C troughs (that is, 10,000). This procedure was repeated at each investigated body weight for the 3 target values (1, 4 and 5.7 mg/l). The number of performed simulations was considered large enough to accurately determine the probability of target attainment in the general population.
To verify the agreement between the model and the data, the probabilities to achieve the target C troughs with the 400/100 mg twice-daily regimen that were obtained from Monte Carlo simulations, were compared wtih the same probabilities calculated from the observed C troughs of the database.
Observed C troughs were defined as concentrations measured between 10 and 14 h after drug intake. To calculate the observed percentages with respect to body weight, patients were also classified according to their body weight into 4 groups: 45-55, 56-65, 66-75 and 76-85 kg, which allowed these groups to be comparable to the 50, 60, 70 and 80 kg body weight groups of the Monte Carlo simulations. Each observed group had to contain at least 30 values.
Results
Demographic data
In total, 764 samples obtained from 424 patients ranging in age from 18 to 75 years (median 40 years) were available for pharmacokinetic evaluation. The studied population comprised 216 (51%) men and 208 (49%) women. A total of 262 patients were Caucasian, 143 were Black and 19 were Asian. Median (range) value for body weight was 67 kg (35.7-125.0). The mean ±sd number of samples per patients was 2 ±1.6.
LPV was combined with ≥1 nucleoside reverse transcriptase inhibitor (NRTI), 1 PI other than RTV, or a non-NRTI in 85%, 16% and 14% of the patients, respectively. Lamivudine was the NRTI most frequently combined with LPV, in 42% of the patients. Nevirapine was combined with LPV only in 4% of the patients, whereas efavirenz was combined with LPV in 10% of the patients.
Among the patients, 84% received the standard 400/100 LPV/RTV twice-daily dose, 10% received a 600/150 LPV/RTV twice-daily dose, 2% a 800/200 LPV/RTV twice-daily dose and 4% had a once-daily dosing regimen, with doses ranging between 400/100 to 1,200/300 mg LPV/RTV. A total of 63% of the samples were drawn after the evening dose and the remaining 37% were drawn after the morning dose. Viral load was obtained for 348 samples. In total, 186 (53%) of these viral loads were undetectable (<50 copies/ml).
Population pharmacokinetics
The classical one-compartment model with first-order absorption (subroutines ADVAN2 and TRANS2) satisfyingly described the data. The one-compartment model with zero-order absorption and the two-compartment model did not improve the fit. Interpatient variability was described by an exponential error model, whereas residual variability was described by a combined exponential and additive error model. Interindividual variability of the absorption rate constant (k a ) could not be estimated. A significant covariance term was found between the deviations between individual and population values (η) of CL/F and V/F.
The use of body weight as a covariate was found to improve the fit. Ethnicity has no significant influence. Among the concomitantly administered antiretroviral agents, a significant interaction was found with efavirenz, nevirapine and amprenavir, which increased LPV CL/F. The best fit was nevertheless obtained when these drugs were simultaneously considered as a single covariate representing the inducing drugs. The estimated values of the parameters of the final model are displayed in Table 1 .
The final covariate submodel was: CL/F (l/h) =4.61×(body weight/65) 0.39 × inducing drugs and V/F (l)=63.2, where inducing drugs is equal to 1.25 if efavirenz or amprenavir or nevirapine was combined with LPV (and 1 if not).
Model validation
The goodness of fit was also evaluated graphically by the lack of bias on the graphs representing the normalized prediction errors versus time and predicted concentration ( Figure 1A and 1B) .
No bias was also observed on the visual predictive checks as the LPV observed concentrations were symmetrically distributed around the median and 2% of the concentrations were outside the 95% confidence interval (not shown).
Evolution of lopinavir exposure with respect to body weight
Probabilities to achieve the three target C troughs (1, 4 and 5.7 mg/l) with respect to body weight for the three dosing regimens of 400/100 mg and 600/150 mg LPV/ RTV twice daily, and 800/200 LPV/RTV once-daily are shown in Figure 2 . For twice-daily regimens, the probability of C trough >1 mg/l remained >96% over the whole
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body weight range irrespective of the daily dose, but an important weight-related decrease in the probability to achieve the target C troughs of 4 and 5.7 mg/l for PI-pretreated patients was evidenced. These probabilities increased with LPV/RTV dose. For example, for a typical 70 kg patient, the probability to achieve the 4 mg/l C trough was 68% and 86% for the 400/100 mg and 600/150 mg twice-daily dose, respectively, whereas for a target C trough of 5.7 mg/l these probabilities were 45% and 70% for the same respective doses. A good agreement was observed with the probabilities calculated from observed C troughs (Table 2) . For the 800/200 mg once-daily regimen, the probabilities to achieve the 1 mg/l C trough tended to be lower than those obtained with twice-daily regimens. Indeed, probabilities to attain the adequate concentrations for PI-experienced patients were very low and ranged between 48% and 13%.
Discussion
The pharmacokinetics of LPV was well described by the one-compartment model we developed, which indicated a relationship between the interindividual variability of CL/F and body weight. The estimated pharmacokinetic parameters were in agreement with previous results (Table 3) .
The previously suggested effect of body weight on LPV concentrations [7] is confirmed by the present study. The Monte Carlo simulations showed that for a treatment-naive patient, whose target LPV C trough is 1 mg/l, the currently used dosing regimen of 400/100 mg twice-daily LPV/RTV seems appropriate independently of body weight (probability to achieve target concentration >96%). On the contrary, for PI-pretreated patients, this same dosage appears suboptimal. Indeed, the probability to achieve the previously described 4 mg/l and 5.7 mg/l target concentrations falls markedly with increasing body weight until reaching the respective values of 61% and 38% for a 90 kg patient. These probabilities increased with the dose; thus, a 600/150 mg twice daily regimen seems to be more appropriate for PI-pretreated patients.
The 800/200 mg once-daily regimen that was approved for PI-naive patients displayed lower probabilities to achieve the different target C troughs compared with the twice-daily regimens. This is in accordance with the lower C trough obtained with the 800/200 oncedaily compared wtih the 400/100 twice-daily dose [10] . Indeed, the probabilities to attain the target C trough for PI-experienced patients were very low, which supports the inappropriateness of the 800/200 mg once-daily regimen in this context.
Body weight is an imprecise measure of patient size because it cannot reflect obesity. Body mass index (BMI) could be a more appropriate measure to reflect the influence of body size on pharmacokinetics. In the present study, height, and therefore BMI, was obtained from Body weight, kg Probability to acheive the target C trough p>1 mg/l, 600 mg twice daily p>1 mg/l, 400 mg twice daily p>1 mg/l, 800 mg once daily p>5.7 mg/l, 400 mg twice daily p>5.7 mg/l, 800 mg once daily p>5.7 mg/l, 600 mg twice daily p>4 mg/l, 400 mg twice daily p>4 mg/l, 800 mg once daily p>4 mg/l, 600 mg twice daily 132 patients only, which precluded its use as a covariate. However, linear regression displayed a lack of significant relationship between BMI and the individual η values for CL/F obtained with the final model (not shown), suggesting BMI did not provide any supplemental information compared with body weight in this subset of the population study.
Concerning the other tested covariates, the increase in LPV clearance caused by efavirenz [11] , nevirapine [12] , amprenavir [13] and the absence of circadian variation in LPV pharmacokinetics [14] was confirmed by our study. Nevertheless, because samples were usually drawn before midday, samples drawn after the morning dose corresponded to peak concentrations, whereas samples drawn after the evening dose corresponded to C troughs . This might have been a source of bias for the study of the possible circadian variation in LPV pharmacokinetics. Ethnicity might explain the interindividual variability in the pharmacokinetics of drugs metabolized by cytochrome P450 3A4 (CYP3A4) because of interethnic differences in the frequency of some polymorphisms of the genes coding for CYP3A4 and/or CYP3A5 [15] . This was not confirmed in the present study. It is likely the systematic combination with RTV, which inhibits CYP3A4 and CYP3A5, balanced the genetic variability.
RTV increases LPV systemic exposure [16] . However, the measured RTV concentrations could not be investigated as a covariate. Indeed, to be comparable from one patient to another, these concentrations should have been measured at the same time post-dose, which was not the case in our study, as RTV samples were by definition concomitant to LPV samples. Furthermore, the aim of our study was to develop a predictive model for LPV concentrations, and the RTV concentration cannot be used as a predictive marker because it cannot be a priori known.
The key message of the present study is that many PI-pretreated patients cannot achieve efficient LPV exposure with the current 400 mg twice-daily dose, and that an increase in the dose does not guarantee the achievement of these target concentrations. It was also evidenced that, if the risk to obtain an inefficient exposure increases with body weight, non-negligible probabilities of underexposure were already found for patients with low body weight values. Taken together, these results suggest the interest of therapeutic drug monitoring in PI-experienced patients, whatever their body weight. A satisfying approach could consist of an individualization of LPV dose based on target C troughs and/or genotypic inhibitory quotient, using LPV plasma concentration and viral genotype [5, 17, 18] . The present results suggest that therapeutic drug monitoring could also be useful for PI-naive patients receiving the 800/200 mg once-daily regimen and, in case of a C trough <1 mg/l, splitting the dose into two daily intakes of 400/100 mg appears as a reliable solution. Table 3 . Lopinavir pharmacokinetic parameters from the literature and as estimated with our models CL/F, apparent clearance; k a , absorption rate constant; V/F, apparent distribution volume.
Investigating the possible relationship between body weight and LPV immunovirological efficacy in PIpretreated patients is warranted on the basis of of the present results. This relationship was not investigated in the present study because it was not designed for such a pharmacodynamic end point. Furthermore, treatment efficacy is known to be related to many factors (for example, treatment history, number of LPV resistance mutation at baseline, combined antiretroviral drugs anad baseline viral load) that were not recorded in our retrospective study, which precluded a reliable analysis of LPV efficacy.
Although the influence of body weight on pharmacodynamics was not demonstrated, an increase in LPV dosage regimen should be considered for pretreated patients and is more likely to be requested as body weight increases.
Increasing the dosing regimen could raise questions on LPV safety as some studies suggested a possible relationship between LPV exposure and LPV-induced hyperlipidaemia [19, 20] . Taken together, these results highly suggest the potential utility of LPV therapeutic drug monitoring in PI-experienced patients.
In conclusion, the present study has shown that the current recommended LPV/RTV 400 mg/100 mg twicedaily dosage with the new tablet form is appropriate for PI-naive patients, but appears to be suboptimal for many PI-pretreated patients. Some PI-naive patients also might not reach the target concentration with the 800/200 mg once-daily regimen. The usefulness and safety of higher LPV dosage in these patients should be investigated in further studies.
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